Hexoskin in Boston/Cambridge for the 9th Annual Digital Implementation Summit 2026 at Pfizer

October 29, 2026

Hexoskin is proud to sponsor the 9th Annual Digital Implementation Summit this November 3rd hosted at Pfizer in Cambridge, MA.

New sensors and technology offer opportunities for digital measurement that can supplement existing collection strategies to drive medical and pharmaceutical research forward. These new tools makes it possible to operationalize data that was hard to collect before in a clinical trial setting, or provide a new source of information for medical conditions that had few practical or objective measures before recently.

Although investing in digital measures and phenotyping has improved the ROI on clinical trials, by providing earlier signals for safety and efficacy, it's still only the second inning in terms of adoption. The Summit will bring more than 30 speakers and 180 senior leaders in clinical research, operations, and trial design to look at where innovation did deliver measurable value and how best practices enable deployment at scale.

What Hexoskin contributes to clinical research

At Hexoskin, we believe digital measures deliver value when clinical protocols are designed with the patient in mind and with a great training and support of clinical sites. Here’s what we offer:

• A dedicated team that supports your study from protocol design to biostatistical analysis. More than sensors and a software platform for managing data collection across sites and cohorts of patients, our team support you through all the steps of a trial, include site training, tech support, and logistics.
  
• Only FDA-cleared wearable for both cardiac and respiratory markers. The Hexoskin Smart Shirt records 3-lead ECG, dual-channel respiratory inductance plethysmography (RIP), and 3-axis accelerometry, all from one comfortable garment. Respiratory patterns are rarely captured continuously outside the lab, and Hexoskin has pioneered their use for many disease categories.
  
• 112 digital biomarkers from a single device. These range from heart rate variability and breathing patterns to gait, sleep, and physical activity. Sponsors can choose the endpoints that matter for their program without adding devices, or burden, for participants.
• Endpoints and early signals across therapeutic areas. Hexoskin data supports research in neurology, rare diseases, and respiratory disease, among other areas. In rare disease especially, a small population means every data point and patient reported outcome is especially valuable.
• A growing body of evidence. Hexoskin has been used in more than 350 scientific publications. You can browse the literature by field in our online paper database.

Contact our team for more information.